The biotech licenses a China-developed anti-B7-H3 ADC.
ApexOnco Front Page
Recent articles
Armed with $75m the company takes a risky asset into the clinic.
But PFS data are lacking, and there are questions about first and second-line plans.
Three private biotechs enter clinical trials, one targeting KRAS.
But the company still has a lot to prove with ERAS-0015.
The company will start three phase 3 trials of its G12D project this year.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
